XML 18 R9.htm IDEA: XBRL DOCUMENT
v3.22.1

CASH EQUIVALENTS AND MARKETABLE SECURITIES | 3 Months Ended
--- | ---
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract] |
CASH EQUIVALENTS AND MARKETABLE SECURITIES | CASH EQUIVALENTS AND MARKETABLE SECURITIES The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
March 31, 2022 |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 49,827 |  |  | $ | — |  |  | $ | — |  |  | $ | 49,827 |
U.S. government-sponsored entity debt securities | 15,009 |  |  |  |  | (1) |  |  | 15,008 |
Total | 64,836 |  |  | — |  |  | (1) |  |  | 64,835 |
Marketable securities: |  |  |  |  |  |  |
U.S. government-sponsored entity debt securities | 24,788 |  |  | — |  |  | (347) |  |  | 24,441 |
Commercial paper securities | 117,709 |  |  | — |  |  | (384) |  |  | 117,325 |
Corporate debt securities | 17,522 |  |  | — |  |  | (149) |  |  | 17,373 |
Asset-backed securities | 67,890 |  |  | — |  |  | (375) |  |  | 67,515 |
U.S. treasury bills | 2,995 |  |  | — |  |  | — |  |  | 2,995 |
Certificate of deposits | 50,526 |  |  | — |  |  | (121) |  |  | 50,405 |
Total | 281,430 |  |  | — |  |  | (1,376) |  |  | 280,054 |
Total cash equivalents and marketable securities | $ | 346,266 |  |  | $ | — |  |  | $ | (1,377) |  |  | $ | 344,889 |
December 31, 2021 |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 119,919 |  |  | $ | — |  |  | $ | — |  |  | $ | 119,919 |
Total | 119,919 |  |  | — |  |  | — |  |  | 119,919 |
Marketable securities: |  |  |  |  |  |  |
U.S. government-sponsored entity debt securities | 30,700 |  |  | 1 |  |  | (87) |  |  | 30,614 |
Commercial paper securities | 105,792 |  |  | 7 |  |  | (42) |  |  | 105,757 |
Corporate debt securities | 33,723 |  |  | 1 |  |  | (42) |  |  | 33,682 |
Asset-backed securities | 70,807 |  |  | 1 |  |  | (107) |  |  | 70,701 |
Certificate of deposits | 45,116 |  |  | 1 |  |  | (26) |  |  | 45,091 |
Total | 286,138 |  |  | 11 |  |  | (304) |  |  | 285,845 |
Total cash equivalents and marketable securities | $ | 406,057 |  |  | $ | 11 |  |  | $ | (304) |  |  | $ | 405,764 |
The fair value of marketable securities by contractual maturity were as follows (in thousands):
| March 31, 2022 |  | December 31, 2021
Maturing in one year or less | $ | 212,547 |  |  | $ | 197,676 |
Maturing after one year through five years | 82,515 |  |  | 88,169 |
Total | $ | 295,062 |  |  | $ | 285,845 |
Realized gains and losses on the sales of investments were insignificant during the three months ended March 31, 2022 and 2021. The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March 31, 2022 and 2021. The Company had unrealized losses related to its marketable securities for the three months ended March 31, 2022 and 2021. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a continuous unrealized loss position for greater than 12 months as of March 31, 2022 and December 31, 2021. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its cost basis. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March 31, 2022. The unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company’s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company’s ability and intent to hold the investments until maturity, the Company determined that no allowance for credit losses related to its marketable securities was required at either March 31, 2022 or December 31, 2021.

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2209399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2324412 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2176304 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph (b) + Details
Name: | us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration